Cancer immunotherapy
FDA-approved antibodies

Cancer immunotherapy

Section Title: FDA-approved antibodies
Table Section Text: None

Antibody	Brand name	Type	Target	Approval date	Approved treatment(s)

Alemtuzumab	Campath	humanized	CD52	2001	B-cell chronic lymphocytic leukemia (CLL)

Atezolizumab	Tecentriq	humanized	PD-L1	2016	bladder cancer

Avelumab	Bavencio	human	PD-L1	2017	metastatic Merkel cell carcinoma

Ipilimumab	Yervoy	human	CTLA4	2011	metastatic melanoma

Ofatumumab	Arzerra	human	CD20	2009	refractory CLL

Nivolumab	Opdivo	human	PD-1	2014	unresectable or metastatic melanoma, squamous non-small cell lung cancer, Renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, classical hodgkin lymphoma

Pembrolizumab	Keytruda	humanized	PD-1	2014	unresectable or metastatic melanoma, squamous non-small cell lung cancer (NSCLC), Hodgkin's lymphoma, Merkel-cell carcinoma (MCC), primary mediastinal B-cell lymphoma (PMBCL), stomach cancer, cervical cancer

Rituximab	Rituxan, Mabthera	chimeric	CD20	1997	non-Hodgkin lymphoma

Durvalumab	Imfinzi	human	PD-L1	2017	bladder cancer non-small cell lung cancer

Sentence(s)

Ofatumumab is a human antibody to CD20.
Ofatumumab is a human antibody that binds to CD20.
The Ofatumumab is a human antibody that binds to CD20.

final_sentence: Ofatumumab is a human antibody to CD20.
final_sentence: Ofatumumab is a human antibody that binds to CD20.
final_sentence: The Ofatumumab is a human antibody that binds to CD20.